InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Contineum Therapeutics, Inc.

CTNM Clue Score32
United States Fiscal year ends December CIK 0001855175 Results filed 3 Nov 2026
Add to watchlist

What the insiders did Scheduled selling only

Individual transactions

31
Insider
Date
Role
Action
Shares
Price
Amount
Carmine N. Stengone
8 Sep 2026
CEO and President
Sold after exercise
2,500
$16.46
$41.14K
Carmine N. Stengone
3 Aug 2026
CEO and President
Sold after exercise
2,500
$16.01
$40.03K
Daniel S. Lorrain
9 Jul 2026
Chief Scientific Officer
Sold after exercise
25
$16.00
$400.00
Carmine N. Stengone
8 Jul 2026
CEO and President
Sold after exercise
2,500
$16.00
$40.00K
Daniel S. Lorrain
8 Jul 2026
Chief Scientific Officer
Sold after exercise
1,015
$16.00
$16.24K
Daniel S. Lorrain
1 Jul 2026
Chief Scientific Officer
Sold after exercise
2,501
$16.24
$40.61K
Daniel S. Lorrain
1 Jul 2026
Chief Scientific Officer
Sold after exercise
5,852
$15.67
$91.68K
Carmine N. Stengone
30 Jun 2026
CEO and President
Sold after exercise
10,000
$16.01
$160.08K
Tim Watkins
30 Jun 2026
CMO & Head of Development
Sold after exercise
10,833
$16.02
$173.59K
Daniel S. Lorrain
30 Jun 2026
Chief Scientific Officer
Sold after exercise
28,826
$16.04
$462.29K
Daniel S. Lorrain
1 Jun 2026
Chief Scientific Officer
Sold on a plan
4,170
$13.16
$54.86K
Daniel S. Lorrain
1 May 2026
Chief Scientific Officer
Sold on a plan
300
$13.84
$4.15K
Daniel S. Lorrain
1 May 2026
Chief Scientific Officer
Sold on a plan
3,870
$13.06
$50.54K
Daniel S. Lorrain
6 Apr 2026
Chief Scientific Officer
Sold on a plan
4,170
$13.43
$56.01K
Tim Watkins
2 Mar 2026
CMO & Head of Development
Sold after exercise
3,611
$15.02
$54.22K
Daniel S. Lorrain
2 Mar 2026
Chief Scientific Officer
Sold on a plan
4,170
$15.01
$62.59K
Daniel S. Lorrain
25 Feb 2026
Chief Scientific Officer
Sold after exercise
3,824
$16.01
$61.23K
Carmine N. Stengone
25 Feb 2026
CEO and President
Sold after exercise
2,700
$16.02
$43.24K
Daniel S. Lorrain
24 Feb 2026
Chief Scientific Officer
Sold after exercise
4,300
$16.03
$68.94K
Carmine N. Stengone
24 Feb 2026
CEO and President
Sold after exercise
4,400
$16.02
$70.49K
Daniel S. Lorrain
19 Feb 2026
Chief Scientific Officer
Sold after exercise
100
$16.00
$1.60K
Daniel S. Lorrain
11 Feb 2026
Chief Scientific Officer
Sold after exercise
400
$16.00
$6.40K
Carmine N. Stengone
11 Feb 2026
CEO and President
Sold after exercise
400
$16.00
$6.40K
Daniel S. Lorrain
3 Feb 2026
Chief Scientific Officer
Sold on a plan
1,170
$15.25
$17.84K
Daniel S. Lorrain
3 Feb 2026
Chief Scientific Officer
Sold on a plan
3,000
$14.82
$44.47K
Tim Watkins
28 Jan 2026
CMO & Head of Development
Sold after exercise
811
$14.48
$11.75K
Tim Watkins
28 Jan 2026
CMO & Head of Development
Sold after exercise
2,800
$14.09
$39.44K
Daniel S. Lorrain
5 Jan 2026
Chief Scientific Officer
Sold on a plan
500
$11.13
$5.56K
Daniel S. Lorrain
5 Jan 2026
Chief Scientific Officer
Sold on a plan
3,670
$10.35
$37.98K
Tim Watkins
29 Dec 2025
CMO & Head of Development
Sold after exercise
3,611
$12.06
$43.56K
Daniel S. Lorrain
23 Dec 2025
Chief Scientific Officer
Sold on a plan
4,170
$12.23
$51.01K

What was left out

Form 4 filings counted 33
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 10
Sales straight out of an exercise 21
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 89,339
History held since 11 Apr 2024